Publications by authors named "M d'Elbee"
Objective: To review HIV testing services (HTS) costs in sub-Saharan Africa.
Design: A systematic literature review of studies published from January 2006 to October 2020.
Methods: We searched ten electronic databases for studies that reported estimates for cost per person tested ($pptested) and cost per HIV-positive person identified ($ppositive) in sub-Saharan Africa.
Introduction: HIV self-testing (HIVST) is a promising strategy to improve diagnosis coverage among key populations (KP). The ATLAS (Auto Test VIH, Libre d'Accéder à la connaissance de son Statut) programme implemented HIVST in three West African countries, distributing over 380,000 kits up between 2019 and 2021, focussing on community-led distribution by KP to their peers and subsequent secondary distribution to their partners and clients. We aim to evaluate the cost-effectiveness of community-led HIVST in Côte d'Ivoire, Mali and Senegal.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the potential benefits of decentralizing childhood tuberculosis diagnosis to lower health system levels, aiming to improve case detection and reduce under-diagnosis.
- It compares two strategies: one focused on district hospitals and another on primary health centers, against the standard of care across six countries.
- The results indicate that while the district hospital approach may be more cost-effective in some settings, both strategies require significant budget increases for implementation, varying by country.
Article Synopsis
- This study assesses the costs associated with an HIV self-testing distribution program in Eswatini, detailing both community-based and workplace delivery models from April 2019 to March 2020.
- Over the 12-month period, 19,155 HIV self-test kits were distributed to 13,031 individuals, with a higher distribution rate in community settings compared to workplaces.
- Key financial figures indicated that personnel accounted for 60% of costs, while the average cost per kit distributed was $17.23, with significantly higher costs associated with clients who tested positive and initiated antiretroviral therapy (ART).